Population Pharmacokinetics of Lamivudine in Adult Human Immunodeficiency Virus-Infected Patients Enrolled in Two Phase III Clinical Trials

Lamivudine population pharmacokinetics were investigated by using nonlinear mixed-effect modelling (NONMEM) analysis of data from 394 human immunodeficiency virus (HIV)-infected patients treated with lamivudine (150 to 300 mg every 12 h) in two large, phase III clinical efficacy-safety trials, NUCA3...

ver descrição completa

Detalhes bibliográficos

Publicado no:	Antimicrob Agents Chemother
Principais autores:	Moore, Katy H. P., Yuen, Geoffrey J., Hussey, Elizabeth K., Pakes, Gary E., Eron, Joseph J., Bartlett, John A.
Formato:	Artigo
Idioma:	Inglês
Publicado em:	American Society for Microbiology (ASM) 1999
Assuntos:	Antiviral Agents
Acesso em linha:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC89609/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/10582904/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.43.12.3025
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!